Followers | 660 |
Posts | 47315 |
Boards Moderated | 1 |
Alias Born | 03/30/2009 |
Thursday, July 29, 2010 8:53:53 PM
These shysters essentially lied through their teeth and caught the whole world with its pants down but it is I who is ultimately responsible for my trades.
JMHO.
Last night the wife said,
Oh boy, when you're dead
You don't take nothing with you
But your soul - think!
--Lennon/McCartney, "The Ballad of John and Yoko"
Recent COEP News
- Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development • PR Newswire (US) • 11/07/2024 01:07:00 PM
- Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use • PR Newswire (US) • 10/24/2024 12:07:00 PM
- Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy • PR Newswire (US) • 10/15/2024 12:07:00 PM
- Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 09/19/2024 11:07:00 AM
- Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders • PR Newswire (US) • 09/05/2024 12:07:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/16/2024 08:02:33 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/16/2024 08:01:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:26:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:25:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 09:00:33 PM
- Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering • PR Newswire (US) • 06/20/2024 12:47:00 PM
- Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting • PR Newswire (US) • 05/30/2024 12:47:00 PM
- Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 • PR Newswire (US) • 05/08/2024 12:47:00 PM
- Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting • PR Newswire (US) • 05/02/2024 12:47:00 PM
- Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award • PR Newswire (US) • 04/02/2024 12:47:00 PM
- Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK • PR Newswire (US) • 02/26/2024 02:00:00 PM
- Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections • PR Newswire (US) • 02/07/2024 12:30:00 PM
- Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 • PR Newswire (US) • 01/04/2024 12:30:00 PM
FEATURED Key Metals Surge, Unlocking New Opportunities for Savvy Mining Investors • Nov 19, 2024 8:45 AM
FEATURED Greenlane Signs New U.S. Distribution Agreement with Veriteque USA, Manufacturer of the SwabTek™ and Verifique™ Brand of Field Test Kits • Nov 19, 2024 8:34 AM
Geo-Political Tensions and Trump's Increasing Military Budgets Could Boost Demand for Actelis' Cyber Hardened Networking Tech ($ASNS) • ASNS • Nov 19, 2024 10:24 AM
CBD Life Sciences Inc. (CBDL) Closes on LOI for Potential $8 Million Revenue Cannabis Dispensary • CBDL • Nov 19, 2024 8:00 AM
Are we about to see a comeback? Steakholder Foods Charges Forward with New Commitments from Multiple International Players as it Transitions to Revenue Generation • STKH • Nov 18, 2024 11:56 AM
North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • NBRI • Nov 18, 2024 9:00 AM